Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
Open Access
- 21 August 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1238876
Abstract
Although combination therapy including chemotherapy and immune checkpoint inhibitors (ICIs) improves overall survival (OS) of patients with non-small-cell lung cancer (NSCLC), there is a higher incidence of adverse events and treatment discontinuation. Since programmed death-ligand 1 (PD-L1) could not serve as a predictive biomarker, we investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictive biomarker. In our previous research, we demonstrated that a low NLR could predict survival benefits when patients with high PD-L1 expression (> 50%) received chemoimmunotherapy as opposed to immunotherapy alone. In this current study, our objective is to evaluate this predictive capacity in patients with low PD-L1 expression (< 50%). A total of 142 patients were enrolled, 28 receiving combination therapy and 114 receiving chemotherapy alone. Progression-free survival (PFS) and OS were estimated using the Kaplan-Meier method and compared using the log-rank test. Patients who received combination therapy had significantly better PFS and OS than those who received monotherapy. In the subgroup of patients with low NLR, those who received combination therapy exhibited extended PFS and OS with clinical significance, which was also confirmed by multivariate Cox regression analysis. Our study demonstrates the potential use of NLR as a biomarker for predicting survival benefits when receiving combination therapy with chemotherapy and ICIs in patients with advanced NSCLC and low PD-L1 expression.Keywords
This publication has 33 references indexed in Scilit:
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2018
- Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality TherapyThe Oncologist, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Clinical significance of preoperative neutrophil–lymphocyte vs platelet–lymphocyte ratio in primary operable patients with non–small cell lung cancerThe American Journal of Surgery, 2015
- Prognostic Significance of Preoperative Neutrophil–Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete ResectionAnnals of Surgical Oncology, 2015
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2014
- Response Criteria in Oncologic Imaging: Review of Traditional and New CriteriaRadioGraphics, 2013
- Neutrophil/lymphocyte ratio and its association with survival after complete resection in non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Cancer-related inflammationNature, 2008
- Cancer immunoediting from immune surveillance to immune escapeImmunology, 2007